ClinicalTrials.gg
Active, not recruitingNCT05703516Updated Nov 17, 2026

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

An observational study in Non-Small-Cell Lung Carcinoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 10 sites in South Korea. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Started
2023
with 2 others
Observational
5 of 101
none open now
Primary completion
2026-11
later than 0 of 14 live
Registered
91st of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is one of 3 that started in 2023, is one of 5 observational ones, reaches primary completion later than 0 of the 14 other live ones, and was the 91st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of Food and Drug Safety).

Read the detailed description

The study is a post approval surveillance so there will be no comparator arm/drug nor blinding process.

Dose/regimen should follow locally approved label and it could be adjusted as per the decision from treating physician during treatment period, under their routine clinical practice. Treatment duration is deemed to the decision from treating physician under their routine clinical practice, since this study is a post approval surveillance and to look for safety profiles happening under real world practice. There will be no intervention from Novartis regarding dose/regimen and treatment duration.

This study will be completed after data collection of the last subject during the follow up period. The follow up period is recommended for up to 24 weeks after enrollment or up to the time of discontinuation of study drug (in case of early discontinuation) as per linical judgement of treating physician.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma

Keywords

  • Non Small Cell Lung
  • Non Small Cell Lung Cancer
  • Non-small cell lung cancer
  • NSCLC
  • INC280
  • Non-small cell lung carcinoma (NSCLC)
  • lung cancer
  • lung adenocarcinoma
  • Non small cell lung carcinoma
  • MET exon 14 deletion
  • METex14del
  • MET exon 14 skipping
  • MET exon 14 mutation
  • MET mutation
  • MET amplification
  • MET inhibitor
  • MET dysregulation
  • MET activation
  • MET signaling
  • MET pathway
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who receive Tabrecta® (Capmatinib) as per locally approved label.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Subject who are diagnosed as exon 14 skipping mutated NSCLC from tissue or plasma(ctDNA) sample analysis by treating physician (i.e. Any kind of diagnostic methods the institution currently has. Diagnostic modalities for research purpose would be also allowable.)
  • Subject who plan to receive Tabrecta® (Capmatinib) as per locally approved label

Exclusion criteria

Exclusion Criteria:

  • Subject with according to the locally approved label
  • Subject whose medical record is not accessible
  • Subject who are not willing to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Capmatinib

    Participants will be treated with capmatinib as per locally approved label

    Other: Capmatinib

Interventions

  • OtherCapmatinib

    There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis

    Also known as: Tabrecta

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs).

    The number of participants with AEs and SAEs will be assessed

    Time frame: From date of first study dose to end of study, assessed up to approximately 28 weeks

Secondary outcomes

  1. Objective response rates (ORRs) assessed by investigator

    ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by the investigator.

    Time frame: Up to 24 weeks

  2. Progression Free Survival (PFS)

    PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.

    Time frame: Up to 24 weeks

07

Study locations

10 sites
  • Novartis Investigative Site
    Daegu, Dalseo gu 42602, South Korea
  • Novartis Investigative Site
    Suwon, Gyeonggi-do 16499, South Korea
  • Novartis Investigative Site
    Seoul, Korea 02447, South Korea
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Busan, 49267, South Korea
  • Novartis Investigative Site
    Daejeon, 35365, South Korea
  • Novartis Investigative Site
    Incheon, 21565, South Korea
  • Novartis Investigative Site
    Jeollanam, 519763, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 41 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2023
First posted
Jan 30, 2023
StartActual
Jun 12, 2023
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Nov 30, 2026was Oct 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Incheon, South Korea
Show 1 removed
  • Novartis Investigative Site · Incheon, South Korea
Nov 17, 2026
Primary completion
Oct 31, 2026→Nov 30, 2026
Nov 17, 2026
Study completion
Oct 31, 2026→Nov 30, 2026
Nov 17, 2026
Enrollment
44 (estimated)→20 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Incheon, South Korea
    Show 1 removed
    • Novartis Investigative Site · Incheon, South Korea
    Primary completion Oct 31, 2026→Nov 30, 2026
    Study completion Oct 31, 2026→Nov 30, 2026
    Enrollment 44 (estimated)→20 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05703516
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Jun 12, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion